| Title: | Substituted heterocycle fused gamma-carbolines |
| Abstract: | The present invention is directed to certain novel compounds represented by structural Formula (I) ##STR00001## or pharmaceutically acceptable salt forms thereof, wherein R.sup.1, R.sup.5, R.sup.6a, R.sup.6b, R.sup.7, R.sup.8, R.sup.9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility. |
| Inventor(s): | Robichaud; Albert J. (Landenberg, PA), Lee; Taekyu (Wilmington, DE), Deng; Wei (Wilmington, DE), Mitchell; Ian S. (Philadelphia, PA), Yang; Michael Guang (Wilmington, DE), Haydar; Simon (Niskayuna, NY), Chen; Wenting (Exton, PA), McClung; Christopher D. (Wilmington, DE), Calvello; Emile J. B. (Bryn Mawr, PA), Zawrotny; David M. (Moorestown, NJ), Rajagopalan; Parthasarathl (Chennai, IN) |
| Assignee: | Bristol-Myers Squibb Pharma Company (Princeton, NJ) |
| Application Number: | 11/356,421 |
Patent Claim Types:
see list of patent claims | Use; Composition; Compound; |
